A totally redesigned host/vector system with improved : properties in terms
of safety has been developed. The pCOR plasmids are narrow-host range plas
mid vectors for nonviral gene therapy. These plasmids contain a conditional
origin of replication and must be propagated in a specifically engineered
E. coli host strain, greatly reducing the potential for propagation in the
environment or in treated patients. The pCOR backbone has several features
that increase safety in terms of dissemination and selection: (1) the origi
n of replication requires a plasmid-specific initiator protein, pi protein,
encoded by the pir gene limiting its host range to bacterial strains that
produce this transacting protein; (2) the plasmid's selectable marker is no
t an antibiotic resistance gene but a gene encoding a bacterial suppressor
tRNA. Optimized E. coli hosts supporting pCOR replication and selection wer
e constructed. High yields of supercoiled pCOR monomers were obtained (100
mg/l) through fed-batch fermentation. pCOR vectors carrying the luciferase
reporter gene gave high levels of luciferase activity when injected into mu
rine skeletal muscle.